The pan-Canadian Pharmaceutical Alliance engaged the Canadian Agency for Drugs and Technologies in Health to lead a multiphase stakeholder consultation process to encourage biosimilar uptake.
Canadian provinces are moving to adopt biosimilars in publicly funded drug plans, and in early 2020, the pan-Canadian Pharmaceutical Alliance (pCPA) will receive a stakeholder report intended to increase uptake even further.
pCPA engaged the Canadian Agency for Drugs and Technologies in Health (CADTH) to lead a multiphase stakeholder consultation process. The project started a few months ago with more than 20 key informant interviews, centered around 5 clinical areas: dermatology, endocrinology, gastroenterology, ophthalmology, and rheumatology.
Stakeholders include clinicians, patient group leaders, private payers, group purchasing organizations, and industry representatives; the project aims to ensure that their perspectives about biosimilars can be captured and conveyed to policymakers.
Last month, there was a 1-day meeting focused on 2 sessions. The morning session featured presentations and discussions for both originator and biosimilar industry representatives. Later in the day, clinicians and patients met without industry present.
During the meeting, participants discussed various policy options designed to increase uptake of biosimilars, including new starts only, tiering, quotas, non-medical switching, and tendering.
Last week, Alberta became the latest province to mandate a non-medical switch to biosimilars, joining British Columbia and Manitoba. Ontario is also considering the same move.
In 2017, pCPA engaged Cancer Care Ontario to lead a pan-Canadian Oncology Biosimilars Initiative, another stakeholder engagement process with the goal of ensuring that the implementation and use of therapeutic oncology biosimilars are appropriate and cost-effective across Canada.
Last year, the pCPA published the Biologics Policy Directions and pCPA Negotiations document with the goal of developing a clear and consistent pan-Canadian approach to biologic medicines across Canada for both originator products and biosimilars.
The final report will be provided to pCPA and its member jurisdictions in early 2020.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).